NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations
Phase 3 Trial Success:
NewAmsterdam Pharma's experimental heart drug, obicetrapib, a CETP inhibitor, met its main goal in a Phase 3 trial by reducing LDL (bad) cholesterol levels in patients with heterozygous familial hypercholesterolemia12.
Disappointing Investor Response:
Despite the trial success, the results fell short of investor and analyst expectations, leading to a drop in the company's stock price12.
Cholesterol Reduction:
The drug, when used alongside other medicines, reduced LDL cholesterol levels by 36% after three months and by 41% after one year, adjusted for placebo1.
Safety Profile:
The drug's safety was comparable to placebo, with no significant side effects observed, unlike previous CETP inhibitors1.
Ongoing Studies:
NewAmsterdam has several ongoing late-stage trials, including one in patients with atherosclerotic cardiovascular disease, with results expected by the end of the year1.
Market Competition:
The drug faces competition from other cholesterol-lowering therapies, such as generic statins and PCSK9 inhibitors, which have shown more significant LDL reductions1.
Analyst Perspectives:
Some analysts, like Jefferies' Dennis Ding, have defended the findings, suggesting that the drug's effects improving over time and its safety profile are positive indicators1.
Sources:
1. https://finance.yahoo.com/news/newamsterdam-heart-drug-hits-trial-110500949.html
2. https://www.fiercebiotech.com/biotech/newamsterdams-cholesterol-drug-hits-phase-3-again-and-disappoints-investors-again